0      0

AONN+ Annual 2020


FRI14 - Product Theater 4 | Treatment of Patients in Newly Diagnosed Multiple Myeloma: Patient Adherence and Dose Modifications in Response to Adverse Events (non-CE) Presentation by Bristol-Myers Squibb


Nov 6, 2020 4:00pm ‐ Nov 6, 2020 5:00pm

Description

This program will share information about a treatment option for newly diagnosed multiple myeloma including the impact of multiple myeloma on patients, dose modifications for consideration due to adverse events, and approaches to keep patients on therapy.

  • Multiple myeloma disease impact
  • Information about a treatment option for patients with NDMM
  • Disease impact of multiple myeloma
  • Dose modifications due to adverse events
  • Patient education and resources

Speaker(s):

You must be logged in and own this session in order to post comments.

Print Certificate
Completed on: token-completed_on
Print Transcript
Please select the appropriate credit type:
/
test_id: 
credits: 
completed on: 
rendered in: 
* - Indicates answer is required.
token-content

token-speaker-name
token-index
token-content
token-index
token-content
token-index
token-content
token-index
token-content
token-index
token-content
token-index
token-content
/
/
token-index
token-content
token-index
token-content